Gay men follow HIV prevention regimen, if MDs prescribe it
(Reuters Health) - Gay and bisexual men who take a Truvada pill daily to prevent infection with HIV did better than researchers expected at sticking to their medication schedule, according to a new report. (Source: Reuters: Health)
Source: Reuters: Health - April 5, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Gilead's Descovy receives FDA approval to treat HIV
American biopharmaceutical company Gilead Sciences has secured approval from the US Food and Drug Administration (FDA) for Descovy (emtricitabine 200mg/tenofovir alafenamide 25mg, F/TAF) to treat patients with HIV. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 4, 2016 Category: Pharmaceuticals Source Type: news
FDA Approves Descovy (emtricitabine and tenofovir alafenamide), Gilead’s Third TAF-Based HIV Therapy
FOSTER CITY, Calif., April 04, 2016 --(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF), a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 4, 2016 Category: Drugs & Pharmacology Source Type: news
AIDS activists go bare to target austerity
With critical HIV treatment deemed too expensive for the NHS, ACT UP London takes on pharmaceutical companies and austerity cuts. Today, on April 1, as part of a global series of direct actions in cities on five continents, naked activists from ACT UP London stood in the lobby of the pharmaceutical company Gilead Sciences, displaying the slogan “Pharma Greed Kills”. Gilead produces Truvada, a type of pre-exposure prophylaxis (PrEP) which is used to treat HIV in adults and teenagers. Yet at £446 per month, Truvada’s price makes it too expensive for it to be viably considered under the National Health Service.Whilst t...
Source: Guardian Unlimited Science - April 1, 2016 Category: Science Authors: Bilal Zenab Ahmed Tags: Science Aids and HIV Austerity Health policy Source Type: news
Odefsey (Emtricitabine, Rilpivirine, and Tenofovir Alafenamide Fixed-dose Combination Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 16, 2016 Category: Drugs & Pharmacology Source Type: news
Drugs that prevent HIV infection are 'less effective in women'
Scientists at the University of North Carolina found the drug Truvada accumulates in different concentrations in vaginal, cervical and rectal tissues - meaning twice as much is needed to protect women from HIV. (Source: the Mail online | Health)
Source: the Mail online | Health - March 10, 2016 Category: Consumer Health News Source Type: news
One dose does NOT fit all for HIV: Drugs that prevent infection are 'less effective in women - meaning they need higher doses'
Scientists at the University of North Carolina found the drug Truvada accumulates in different concentrations in vaginal, cervical and rectal tissues - meaning twice as much is needed to protect women from HIV. (Source: the Mail online | Health)
Source: the Mail online | Health - March 7, 2016 Category: Consumer Health News Source Type: news
Study: Women need more Truvada than men to prevent HIV infection
Stephen FellerCHAPEL HILL, N.C., March 4 (UPI) -- Women require more of the drug Truvada to prevent HIV infection than men, according to a new study conducted at the University of North Carolina. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 4, 2016 Category: Consumer Health News Source Type: news
Women need more of the HIV drug Truvada than men to prevent infection
Women need daily doses of the antiviral medication Truvada to prevent HIV infection while men only need two doses per week due to the way the drug accumulates in different body tissues, according to a new study from pharmacy researchers. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 4, 2016 Category: Science Source Type: news
FDA Clears Gilead's Second TAF-Based HIV Regimen (Odefsey)FDA Clears Gilead's Second TAF-Based HIV Regimen (Odefsey)
Odefsey combines emtricitabine, rilpivirine, and tenofovir alafenamide and 'represents the smallest pill of any single tablet regimen for the treatment of HIV,' the company says. FDA Approvals (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 3, 2016 Category: Infectious Diseases Tags: HIV/AIDS News Alert Source Type: news
FDA Approves Odefsey (emtricitabine, rilpivirine and tenofovir alafenamide) for the Treatment of HIV-1 Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar. 1, 2016-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 1, 2016 Category: Drugs & Pharmacology Source Type: news
Truvada to prevent HIV approved in Canada
Health Canada has approved a daily HIV prevention pill in combination with safer sex practices, the drug’s manufacturer says. (Source: CBC | Health)
Source: CBC | Health - February 29, 2016 Category: Consumer Health News Tags: News/Health Source Type: news
CHMP Backs Emtricitabine/Tenofovir Alafenamide for HIVCHMP Backs Emtricitabine/Tenofovir Alafenamide for HIV
The combo, called Descovy, is an alternative treatment option to Gilead's tenofovir disoproxil fumarate (Viread) and is expected to have similar efficacy, the committee said. International Approvals (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - February 26, 2016 Category: Infectious Diseases Tags: HIV/AIDS News Alert Source Type: news
NIH-funded study finds effect of PrEP on bone density is reversible
(NIH/National Institute of Allergy and Infectious Diseases) The slight loss in bone mineral density associated with HIV pre-exposure prophylaxis (PrEP) antiretroviral use is reversible in young adult patients who stop taking the drugs, according to findings presented by researchers today at the 23rd Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. PrEP is an HIV prevention strategy in which at-risk HIV-negative people take a daily pill of Truvada, which contains the antiretroviral drugs tenofovir and emtricitabine, to prevent them from becoming infected. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 23, 2016 Category: Infectious Diseases Source Type: news
Cuomo’s Proposal Seeks Confidentiality for Minors With H.I.V.
The governor’s office said that the plan would help remedy situations in which teenagers cannot seek H.I.V. treatment without parental consent. (Source: NYT Health)
Source: NYT Health - February 11, 2016 Category: Consumer Health News Authors: SHARON OTTERMAN Tags: Acquired Immune Deficiency Syndrome Cuomo, Andrew M New York State Teenagers and Adolescence Truvada (Drug) Source Type: news
